Letztes “update” :
19/11/2024
Antikrebsmittel   Carboplatin  
Injektion
Stabilität der Lösung Gemengestabilität Stabilitätbeeinflussende Faktoren Kompatibilitäten Applikationsart Literaturverzeichnis pdf
   Chemische Struktur  

Handelsmarke   Handelsmarke     

Handelsnamen sind als beispielhaft anzusehen. Sonstige Bestandteile können je nach Hersteller oder Land verschieden sein

Acoplasic Mexiko
Axicarb Deutschland
Balidon Kolumbien
Blastocarb Chile, Kolumbien, Mexiko, Peru
Boplatex Ecuador, Kolumbien, Mexiko
Carbip Mexiko
Carbodex Türkei
Carboeen Indien
Carbokebir Argentinien
Carbokem Indien
Carbol Peru
Carbomedac Schweden
Carboplat Argentinien, Deutschland, Mexiko
Carboplatin Ägypten, Australien, Belgien, Brasilien, Dänemark, Finnland, Griechenland, Indien, Iran, Irland, Island, Kanada, Luxemburg, Marokko, Neuseeland, Österreich, Saudi-Arabien, Vereinigte Staaten von Amerika
Carboplatine Frankreich, Marokko, Schweiz
Carboplatino Argentinien, Chile, Kolumbien, Spanien
Carbosin Ägypten, Belgien, Griechenland, Malaysia
Cycloplatin Polen, Ungarn
Emorzym Griechenland
Megaplatin Griechenland
Nuvaplast Mexiko
Paraplatin Belgien, Dänemark, Finnland, Griechenland, Großbritannien, Italien, Luxemburg, Mexiko, Niederlande, Norwegen, Österreich, Polen, Schweden, Schweiz, Spanien, Ungarn, Vereinigte Arabische Emirate, Vereinigte Staaten von Amerika
Paraplatine Frankreich, Marokko, Tunesien
Platinwas Spanien
Literaturverzeichnis   Injektion   Literaturverzeichnis : Carboplatin  
Typ Veröffentlichung
3 Zeitung Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
57 Zeitung Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 Zeitung Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Zeitung Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85 Zeitung Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
99 Zeitung Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
163 Zeitung Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA.
Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens.
J Clin Pharm Ther 1994 ; 19: 127-133.
164 Zeitung Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC.
Stability and compatibility of cisplatin and carboplatin with PVC infusion bags.
J Clin Pharm Ther 1994 ; 19: 95-100.
166 Zeitung Rochard E, Barthes D, Courtois P.
Stability and compatibility study of carboplatin with three portable infusion pump reservoirs.
Int J Pharm 1994 ; 101: 257-262.
169 Zeitung Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
244 Zeitung Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Zeitung Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Zeitung Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Zeitung Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Zeitung Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Zeitung Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
409 Zeitung Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP.
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
Am J Hosp Pharm 1987 ; 44: 124-130.
484 Zeitung Northcott M, Allsopp MA, Powell H, Sewell GJ.
The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged “in use” conditions.
J Clin Pharm Ther 1991 ; 16: 123-129.
486 Zeitung Diaz Amador F, Sevilla Azzati E, Herreros de Tajeda y Lopez-Coterilla A.
Stability of carboplatin in polyvinyl chloride bags.
Am J Health-Syst Pharm 1998 ; 55: 602, 604.
492 Zeitung Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
645 Zeitung Sewell GJ, Riley CM, Rowland CG.
The stability of carboplatin in ambulatory continuous infusion regimes.
J Clin Pharm Ther 1987 ; 12: 427-432.
872 Zeitung Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F.
Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions.
Ann Pharmacotherapy 1997 ; 31: 1465-1470.
905 Zeitung Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026 Zeitung Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1410 Zeitung Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Zeitung Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Zeitung Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 Zeitung Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1520 Labor Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1625 Zeitung Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Zeitung Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1667 Zeitung Valière C, Arnaud P, Caroff E, Dauphin JF, Clément G, Brion F.
Stability and compatibility study of a carboplatin solution in syringes for continuous ambulatory infusion.
Int J Pharm 1996 ; 138: 125-128.
1734 Zeitung Hadfield JA, McGown AT, Dawson MJ, Thatcher N, Fox BW.
The suitability of carboplatin solutions for 14-day continuous infusion by ambulatory pump : an HPLC-dynamic FAB study.
J Pharm Biomed Anal 1993 ; 11: 723-727.
1925 Zeitung Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1950 Zeitung Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
1953 Zeitung Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Zeitung Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108 Zeitung Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2203 Zeitung Kaestner S, Sewell G.
A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate 'dose-banding'.
J Oncol Pharm Practice 2007 ; 13: 119-126.
2242 Zeitung Lederer M, Leipzig-Pagani E.
A note on the solution chemistry of carboplatin in aqueous solutions.
Int J Pharm 1998 ; 167, 1-2: 223-228.
2243 Zeitung Pujol M, Girona V, Prat J, Munoz M, De Bolos J.
Degradation pathway of carboplatin in aqueous solution.
Int J Pharm 1997 ; 146: 263-269.
2244 Zeitung Prat J, Pujol M, Girona V, Munoz M, Sol? L-A.
Stability of carboplatin in 5% glucose solution in glass, polyethylene and polypropylene containers.
J Pharm Biomed Anal 1994 ; 12, 1: 81-84.
2245 Zeitung Torres F, Girona V, Puiol M, Prat J, de Bolos J.
Stability of carboplatin in 5% glucose solution exposed to light.
Int J Pharm 1996 ; 129: 275-277.
2247 Zeitung Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2253 Zeitung Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S.
Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS.
J Synchrotron Rad 2001 ; 8: 716-718.
2254 Zeitung Curis E, Provost K, Nicolis I, Bouvet D, B?nazeth S, Crauste-Manciet S, Brion F, Brossard D.
Carboplatin decomposition in aqueous solution with chloride ions monitored by X-ray absorption spectroscopy.
New J Chem 2000 ; 24: 1003-1008.
2262 Zeitung Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3277 Zeitung Yang Z, Cameron S, Paul H.
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration.
Int J Pharm Compound 2012 ; 16, 1 : 82-85.
3286 Zeitung Okamoto Y, Tazumi K, Sanada Y, Tsugane M, Uejima E.
Light-induced Deterioration Test of Carboplatin under Clinical Settings.
Yakugaku Zasshi 2010 ; 130, 10: 1369-1374.
3341 Zeitung Trittler R, Jung B, Strehl E.
Ist teurer immer auch besser? Analytiklabor der Apotheke unterstütz Einkauf sentcheidungen bei Carboplatin-Präparaten.
Krankenhauspharmazie 2001 ; 7: 331-333.
3474 Labor Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3574 Labor Ondansetron - Résumé des caractéristiques du produit
Accord Healthcare France SAS 2013
3602 Labor Mesna (Uromitexan®)- Summary of Product Characteristics
Baxter SAS 2013
3670 Zeitung Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3743 Zeitung Allsopp M.A, Sewell G.J, Rowland C.G, Riley C.M, Schowen R.L.
The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles.
Int J Pharm 1991 ; 69: 197-210.
3830 Zeitung Myers A.Ls, Zhang Y-P, Kawedia L, Trinh V.A, Tran H, Smith J.A, Kramer M.A.
Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags.
J Oncol Pharm Practice 2016 ; 22: 31-36.
4120 Zeitung Vazquez-Sanchez R, Sanchez-Rubio-Ferrandez J, Cordoba-Diaz D, Cordoba-Diaz M, Molina-Garcia T.
Stability of carboplatin infusion solutions used in desensitization protocol.
J Oncol Pharm Practice 2018 25,5:1076?1081
4205 Zeitung Choi S, O La H, Kim K, Kim S, Hwangbo S.
Stability of Carboplatin in normal saline : dependence on initial dilution concentration and storage time.
J Kor Soc Hosp Pharm 2006 ;23,3:219-224
4310 Zeitung Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M.
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.

  Mentions Légales